MVA85A Vaccine and Its Effects on Immune Response
Author Information
Author(s): Griffiths Kristin L., Pathan Ansar A., Minassian Angela M., Sander Clare R., Beveridge Natalie E. R., Hill Adrian V. S., Fletcher Helen A., McShane Helen
Primary Institution: The Jenner Institute, Oxford University, Oxford, United Kingdom
Hypothesis
Does vaccination with the MVA85A vaccine induce changes in ATP consumption and cytokine production in T cells?
Conclusion
Vaccination with MVA85A leads to a decrease in ATP consumption and an increase in IL-17 and IFN-γ production by T cells two weeks post-vaccination.
Supporting Evidence
- ATP consumption significantly decreased two weeks post-vaccination.
- IFN-γ and IL-17 double-producing T cells peaked two weeks after vaccination.
- CD39+ Treg percentages dropped post-vaccination, correlating with ATP consumption.
- IL-17 production was enhanced in vaccinated individuals.
- Vaccination with MVA85A is designed to boost immune responses initiated by BCG.
Takeaway
The MVA85A vaccine helps the body fight tuberculosis by changing how certain immune cells behave, making them better at producing important signals.
Methodology
The study measured ATP consumption and cytokine production in peripheral blood mononuclear cells from vaccinated subjects at various time points post-vaccination.
Potential Biases
Potential conflicts of interest due to authors' involvement in vaccine development.
Limitations
The study primarily focuses on short-term immune responses and does not assess long-term effects of the vaccine.
Participant Demographics
Subjects aged 18-50, previously vaccinated with BCG, seronegative for HIV and hepatitis B and C.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website